Kerry L. Burnstein

4.6k total citations
78 papers, 3.5k citations indexed

About

Kerry L. Burnstein is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kerry L. Burnstein has authored 78 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 34 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Kerry L. Burnstein's work include Estrogen and related hormone effects (34 papers), Prostate Cancer Treatment and Research (32 papers) and Hormonal and reproductive studies (14 papers). Kerry L. Burnstein is often cited by papers focused on Estrogen and related hormone effects (34 papers), Prostate Cancer Treatment and Research (32 papers) and Hormonal and reproductive studies (14 papers). Kerry L. Burnstein collaborates with scholars based in United States, Japan and Australia. Kerry L. Burnstein's co-authors include John A. Cidlowski, Gary G. Schwartz, Christine M. Jewell, Eddy S. Yang, Leah Lyons, Bal L. Lokeshwar, Jia Le Dai, Cale D. Fahrenholtz, Jialin Dai and Jennifer M. Grad and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Kerry L. Burnstein

76 papers receiving 3.4k citations

Peers

Countries citing papers authored by Kerry L. Burnstein

Since Specialization

Citations

This map shows the geographic impact of Kerry L. Burnstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kerry L. Burnstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kerry L. Burnstein more than expected).

Fields of papers citing papers by Kerry L. Burnstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kerry L. Burnstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kerry L. Burnstein. The network helps show where Kerry L. Burnstein may publish in the future.

Co-authorship network of co-authors of Kerry L. Burnstein

This figure shows the co-authorship network connecting the top 25 collaborators of Kerry L. Burnstein. A scholar is included among the top collaborators of Kerry L. Burnstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kerry L. Burnstein. Kerry L. Burnstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer 2023 ·iScience ·(unknown), (unknown), (unknown), (unknown), Kerry L. Burnstein	9
2	Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens 2023 ·PLoS ONE ·(unknown), (unknown), (unknown), Stephan C. Schürer, Kerry L. Burnstein	3
3	Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy? 2022 ·Journal of Clinical Investigation ·(unknown), Marijo Bilušić, Kerry L. Burnstein	5
4	Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer 2019 ·Science Translational Medicine ·Ning Zhao, (unknown), Chen Hao Lo, (unknown), Meghan A. Rice, Cale D. Fahrenholtz, (unknown), (unknown), (unknown), (unknown), Yushan Zhang, Yehia Daaka, Conor C. Lynch, Kerry L. Burnstein	41
5	Abstract A063: Preclinical evaluation of an arginine vasopressin receptor 1A (AVPR1A) antagonist in castration-resistant prostate cancer 2018 ·Cancer Research ·Ning Zhao, (unknown), Chen Hao Lo, (unknown), (unknown), Meghan A. Rice, (unknown), Yushan Zhang, Yehia Daaka, Conor C. Lynch, Kerry L. Burnstein	1
6	Targeting AR Variant–Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities 2017 ·Molecular Cancer Research ·(unknown), (unknown), Meghan A. Rice, (unknown), (unknown), Pablo S. Magani, (unknown), Jonathan Weitz, Kerry L. Burnstein	17
7	Thioredoxin-1 protects against androgen receptor-induced redox vulnerability in castration-resistant prostate cancer 2017 ·Nature Communications ·(unknown), Clara I. Troccoli, (unknown), (unknown), Karen Kage, (unknown), (unknown), Deukwoo Kwon, Yuguang Ban, (unknown), (unknown), Mercè Jordà, Kerry L. Burnstein, Priyamvada Rai	49
8	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity 2016 ·Molecular Cancer Therapeutics ·Thirupandiyur S. Udayakumar, Radka Stoyanova, Mohammed M. Shareef, Zhaomei Mu, (unknown), Kerry L. Burnstein, Alan Pollack	13
9	The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related 2016 ·Oncogene ·Meghan A. Rice, (unknown), (unknown), (unknown), (unknown), Travis J. Yates, Philip Miller, Carlos Perez‐Stable, Priyamvada Rai, Ramiro E. Verdún, Derek M. Dykxhoorn, Kerry L. Burnstein	37
10	Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts 2013 ·Molecular Cancer Therapeutics ·Cale D. Fahrenholtz, Pedro J. Beltran, Kerry L. Burnstein	27
11	A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer 2011 ·Oncogene ·Shuyun Rao, Leah Lyons, Cale D. Fahrenholtz, (unknown), Amjad Farooq, Wayne Balkan, Kerry L. Burnstein	38
12	Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer 2010 ·Endocrine Related Cancer ·Adam Rosenblatt, (unknown), Leah Lyons, Yong Xie, (unknown), Laurent Désiré, J. Slingerland, Kerry L. Burnstein	51
13	Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy 2005 ·Journal of Cellular Biochemistry ·Kerry L. Burnstein	99
14	Evaluation of Vitamin D Analogs as Therapeutic Agents for Prostate Cancer 2003 ·Recent results in cancer research ·Tai C. Chen, Michael F. Holick, Bal L. Lokeshwar, Kerry L. Burnstein, Gary G. Schwartz	29
15	Antiandrogenic activity of extracts of diesel exhaust particles emitted from diesel-engine truck under different engine loads and speeds 2003 ·Toxicology ·(unknown), Ryoichi Kizu, Akira Toriba, Tsuyoshi Murahashi, Atsushi Mizokami, Kerry L. Burnstein, Carolyn M. Klinge, Kazuichi Hayakawa	41
16	A role of aryl hydrocarbon receptor in the antiandrogenic effects of polycyclic aromatic hydrocarbons in LNCaP human prostate carcinoma cells 2003 ·Archives of Toxicology ·Ryoichi Kizu, (unknown), Akira Toriba, Hiroshi Kakishima, Atsushi Mizokami, Kerry L. Burnstein, Kazuichi Hayakawa	93
17	Expression ofRFG/ELE1?/ARA70 in normal and malignant prostatic epithelial cell cultures and lines: Regulation by methylation and sex steroids 2001 ·Molecular Carcinogenesis ·(unknown), Kin‐Mang Lau, John A. Long, Kerry L. Burnstein, Shuk‐Mei Ho	27
18	Hepatocyte Growth Factor and Vitamin D Cooperatively Inhibit Androgen-Unresponsive Prostate Cancer Cell Lines* 2000 ·Endocrinology ·(unknown), Carlos Perez‐Stable, Ralph Schwall, Kerry L. Burnstein, Richard C. Ostenson, Guy A. Howard, Bernard A. Roos	16
19	Multiple Androgen Response Elements and a Myc Consensus Site in the Androgen Receptor (AR) Coding Region Are Involved in Androgen-Mediated Up-Regulation of AR Messenger RNA 1999 ·Molecular Endocrinology ·Jennifer M. Grad, Jia Le Dai, Shu Wu, Kerry L. Burnstein	102
20	Androgen and glucocorticoid regulation of androgen receptor cDNA expression 1995 ·Molecular and Cellular Endocrinology ·Kerry L. Burnstein, (unknown), Jingyao Dai, (unknown)	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact